Most Read Articles
Jairia Dela Cruz, 2 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
11 Sep 2020
Men who use calcium channel blockers (CCBs) are at risk of developing prostate cancer, and the risk increases with the duration of CCB exposure, according to the results of a systematic review and meta-analysis.
06 Sep 2020
Type 2 diabetes mellitus patients taking proton pump inhibitors (PPIs) are at a higher risk of sustaining hip fractures, a recent study has found.
4 days ago
Osteoarthritis (OA) is the most common condition affecting the joints. Dr Lee Eu Jin, an Orthopaedic Surgeon from Liberty Orthopaedic Clinic at Mount Elizabeth Medical Centre, Singapore, shares his insights with Pearl Toh on how to manage OA in the primary care setting.


MUSCAT-HF: No clear evidence of cardioprotection with novel SGLT2 inhibitor in HFpEF

28 Aug 2020

The novel and selective SGLT2 inhibitor luseogliflozin does not seem to produce significant reductions in B‐type natriuretic peptide (BNP) concentrations in patients with type 2 diabetes mellitus (T2DM) and heart failure with preserved ejection fraction (HFpEF) as compared with the alpha‐glucosidase inhibitor voglibose, according to data from the open‐label MUSCAT-HF trial.

In total, 169 T2DM patients with HFpEF were randomized to receive luseogliflozin 2.5 mg once daily (n=86) or voglibose 0.2 mg three times daily (n=85) for 12 weeks. Expansion of follow‐up for an additional 12 weeks was continued in patients who agreed.

Three patients did not receive any doses of a study drug and were excluded from all analyses. The safety population included 166 patients, while the efficacy analysis included 165 patients, 83 in the luseogliflozin (mean age, 71.7 years; 66 percent male) and 82 in the voglibose (mean age, 74.6 years; 59 percent male) groups. BNP was used as the index of the therapeutic effect.

The mean systolic blood pressure and heart rate were similar in the luseogliflozin and voglibose groups. At baseline, the median BNP concentration was 63.7 vs 75.1 pg/mL, respectively, and the median NT‐proBNP concentration was 203 vs 200 pg/mL, respectively.

BNP concentrations decreased over time in the luseogliflozin group. At week 12, the change from baseline was –9.0 percent, which was not significantly different compared with voglibose (−1.9 percent; ratio of change, 0.93, 95 percent confidence interval, 0.78–1.10; p=0.26).

Results for safety outcomes followed a similar pattern. All adverse events and exploratory haemodynamic outcomes were similar between the two groups, except for a significantly lower rate of gastrointestinal symptoms (p=0.013) and greater reduction in systolic blood pressure (p=0.036) with luseogliflozin.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 2 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
11 Sep 2020
Men who use calcium channel blockers (CCBs) are at risk of developing prostate cancer, and the risk increases with the duration of CCB exposure, according to the results of a systematic review and meta-analysis.
06 Sep 2020
Type 2 diabetes mellitus patients taking proton pump inhibitors (PPIs) are at a higher risk of sustaining hip fractures, a recent study has found.
4 days ago
Osteoarthritis (OA) is the most common condition affecting the joints. Dr Lee Eu Jin, an Orthopaedic Surgeon from Liberty Orthopaedic Clinic at Mount Elizabeth Medical Centre, Singapore, shares his insights with Pearl Toh on how to manage OA in the primary care setting.